200 related articles for article (PubMed ID: 32003684)
21. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.
Baggio LL; Kim JG; Drucker DJ
Diabetes; 2004 Dec; 53 Suppl 3():S205-14. PubMed ID: 15561912
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
23. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
24. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
[TBL] [Abstract][Full Text] [Related]
25. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
26. Glucagon-like peptide-1 and control of insulin secretion.
Thorens B
Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
[TBL] [Abstract][Full Text] [Related]
27. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Diabetes; 2004 Sep; 53(9):2492-500. PubMed ID: 15331566
[TBL] [Abstract][Full Text] [Related]
28. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide 1 (GLP-1) and metabolic diseases.
Rotella CM; Pala L; Mannucci E
J Endocrinol Invest; 2005 Sep; 28(8):746-58. PubMed ID: 16277173
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
Gromada J; Brock B; Schmitz O; Rorsman P
Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
[TBL] [Abstract][Full Text] [Related]
31. Glucagon and glucagon-like peptide receptors as drug targets.
Estall JL; Drucker DJ
Curr Pharm Des; 2006; 12(14):1731-50. PubMed ID: 16712485
[TBL] [Abstract][Full Text] [Related]
32. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.
De León DD; Crutchlow MF; Ham JY; Stoffers DA
Int J Biochem Cell Biol; 2006; 38(5-6):845-59. PubMed ID: 16202636
[TBL] [Abstract][Full Text] [Related]
33. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
[TBL] [Abstract][Full Text] [Related]
34. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence.
Serre V; Dolci W; Schaerer E; Scrocchi L; Drucker D; Efrat S; Thorens B
Endocrinology; 1998 Nov; 139(11):4448-54. PubMed ID: 9794451
[TBL] [Abstract][Full Text] [Related]
35. Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats.
Valverde I; Wang GS; Burghardt K; Kauri LM; Redondo A; Acitores A; Villanueva-Peñacarrillo ML; Courtois P; Sener A; Cancelas J; Malaisse WJ; Scott FW
Endocrine; 2004 Feb; 23(1):77-84. PubMed ID: 15034199
[TBL] [Abstract][Full Text] [Related]
36. Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gαq pathway.
Thompson A; Kanamarlapudi V
Biochem Pharmacol; 2015 Jan; 93(1):72-84. PubMed ID: 25449603
[TBL] [Abstract][Full Text] [Related]
37. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
38. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J; Jeon M; Brooks A
Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
[TBL] [Abstract][Full Text] [Related]
39. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Drucker DJ
Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
[TBL] [Abstract][Full Text] [Related]
40. Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery.
Wang MW; Liu Q; Zhou CH
Acta Pharmacol Sin; 2010 Sep; 31(9):1026-30. PubMed ID: 20676118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]